Sartorius and Repligen Launch Upstream Processing Intensification System
Sartorius’ Biostat STR now incorporates Repligen’s XCell ATF hardware.
Sartorius and Repligen Corporation, a bioprocessing focused life sciences company, announced the launch of an integrated bioreactor system on Aug. 17, 2023. Sartorius Biostat Stirred-Tank Reactor (STR) bioreactor now incorporates Repligen’s XCell Alternating Tangential Flow (ATF) upstream intensification technology, which is intended to simplify intensified seed train and N perfusion implementation for biopharmaceutical manufacturers.
According to a company press release, the Biostat STR also now incorporates an embedded XCell ATF hardware and software module that offers predefined advanced control recipes with integrated process analytical technology. This is designed to streamline control of cell growth and improve cell retention in perfusion processes without using a separate cell retention control tower.
“The market introduction of this integrated bioreactor–intensification system created in partnership with Repligen further reinforces Sartorius’ commitment to being an innovator in process intensification and demonstrates our expertise in upstream processing technologies,” said Mario Becker, head, Product Group Bioreactor Technologies, Sartorius, in the release. “Ultimately, our goal is to help customers bring more therapeutics to patients faster, and this launch advances our journey along that path to enable continuous manufacturing.”
“It’s been our pleasure to partner with Sartorius on this program and to share this milestone achievement,” said Christine Gebski, senior vice-president, Filtration & Chromatography, Repligen, in the release. “The successful pairing of our … Cell ATF intensification control technology with Sartorius’ single-use bioreactors provides end users with a simplified, easy-to-implement perfusion-enabled bioreactor solution for more efficient, higher density cell culture processes.”
Source: Sartorius
